Search results
Results From The WOW.Com Content Network
BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes. BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 7.9% Skip to main ...
BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its ...
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida. The company is developing medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA ...
List of largest biomedical companies by market capitalization. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) with current market capitalization of at least US$10 billion, ranked by their market capitalization. It does not include biotechnology companies that ...
Biomarin estimates the price would equate to $900,000 per patient in net revenue, the company said. The estimate is based on average patient weight and number of vials required for the one-time ...
For premium support please call: 800-290-4726 more ways to reach us
Overall, an acquisition of BioMarin would have to come at a premium to today's price to satisfy shareholders, and that means the acquirer wouldn't get much in terms of immediate cost savings.
Drisapersen (also known as Kyndrisa, PRO051 and GSK2402968 [1]) is an experimental drug that was under development by BioMarin, after acquisition of Prosensa, [2] for the treatment of Duchenne muscular dystrophy. The drug is a 2'-O-methyl phosphorothioate oligonucleotide that alters the splicing of the dystrophin RNA transcript, eliminating ...